The Drug Manufacturer as a Drug Information Resource

Cambrey Nguyen

首页> 外文期刊>The Journal of pharmacy technology: jPT : official publication of the Association of Pharmacy Technicians >The Drug Manufacturer as a Drug Information Resource

【24h】

The Drug Manufacturer as a Drug Information Resource

机译：药物制造商作为药物信息资源

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Pharmacists use a myriad of drug resources for patient care; however, the drug manufacturer is often overlooked and underutilized as a resource for drug information. Pharmaceutical companies have a medical information department that is responsible for providing drug information to pharmacists and the public about the company’s products. This article will explain the purpose and functions of the medical information department within a pharmaceutical company. In addition, the type of information that may be requested and the ways to request drug information will be discussed.

机译：药剂师使用大量的药物资源来护理病人；然而，药品生产商作为药品信息资源往往被忽视和利用不足。制药公司有一个医疗信息部门，负责向药剂师和公众提供有关公司产品的药物信息。本文将解释制药公司医疗信息部门的目的和职能。此外，还将讨论可能要求的信息类型和要求药物信息的方式。

著录项

来源
《The Journal of pharmacy technology: jPT : official publication of the Association of Pharmacy Technicians》 |2021年第3期|共4页
作者
Cambrey Nguyen;
展开▼
作者单位

University of Kansas;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类药学;
关键词
pharmaceutical industry; pharmacists; drug information; patient care; drug manufacturer;

机译：制药业;药剂师;药物信息;病人护理;药品制造商;

相似文献

外文文献
中文文献
专利

1. Traditional Chinese medicine is a resource for drug discovery against 2019 novel coronavirus(SARS-CoV-2) [J] . Chang-quan Ling 结合医学学报：英文版 . 2020,第002期
2. Chemoinformatic Resources for Organometallic Drug Discovery [J] . José L. Medina-Franco, Yesenia Cruz-Lemus, Yazmin Percastre-Cruz 计算分子生物学（英文） . 2020,第001期
3. Cyanobacteria, Lyngbya aestuarii and Aphanothece bullosa as antifungal and antileishmanial drug resources [J] . Maheep Kumar, Manoj Kumar Tripathi, Akanksha Srivastava, 亚太热带生物医学杂志（英文版） . 2013,第006期
4. Current FDA-Related Drug Information New Drugs Approved by the FDA New Dosage Forms and Indications Approved by the FDA Agents Pending FDA Approval New Drug/Biologies License Applications Filed by Manufacturer Supplemental Actions Filed by Manufacturer Significant Labeling Changes or "Dear Health Professional" Letters Related to Safety [J] . Danial E. Baker Hospital pharmacy. . 2011,第9期

机译：当前与FDA有关的药物信息由FDA批准的新药物新剂型和适应症，由FDA代理商批准的待批FDA批准的新药/生物许可申请，由制造商提出的补充措施，由制造商提出的重要措施，或与“亲爱的健康专业人员”的信件有关安全
5. Current FDA-Related Drug Information New Drugs Approved by the FDA New Dosage Forms and Indications Approved by the FDA Agents Pending FDA Approval New Drug/Biologies License Applications Filed by Manufacturer Supplemental Applications Filed by Manufacturer Significant Labeling Changes or "Dear Health Professional" Letters Related to Safety [J] . Danial E. Baker Hospital pharmacy. . 2010,第6期

机译：当前与FDA有关的药物信息由FDA批准的新药物，由FDA代理商批准的新剂型和适应症，待FDA批准的制造商提出的新药/生物许可申请，制造商提出的补充申请，重要的标签变更或与“亲爱的健康专业人员”的信件安全
6. New Drugs Approved by the FDA New Dosage Forms and Indications Approved by the FDA Agents Pending FDA Approval New Drug/Biologies License Applications Filed by Manufacturer Supplemental Actions Filed by Manufacturer Significant Labeling Changes or "Dear Health Professional" Letters Related to Safety [J] . Danial E. Baker Hospital pharmacy. . 2011,第11期

机译：FDA批准的新药FDA批准前的FDA代理人批准的新剂型和适应症制造商提出的新药/生物许可申请由制造商提出的补充措施重大标签变更或与安全相关的“亲爱的健康专业人员”信函
7. Sirius: A Resource for Analyzing Drug-Disease Relationships for Drug Repositioning [C] . Muhsin Muhammad Maudarbux, Anisah Wahed Ghoorah, Tulsi Pawan Fowdur International conference on emerging trends in electrical, electronic and communications engineering . 2019

机译：天狼星：用于分析药物排雷的毒性关系的资源
8. A multifaceted approach to tuberculosis drug development: Tapping natural resources, defining specific drug pathogen interactions and identifying novel pathways for drug inhibition by differential protein expression profiling. [D] . Hughes, Minerva A. 2006

机译：结核病药物开发的多方面方法：挖掘自然资源，定义特定的药物病原体相互作用，并通过差异蛋白表达谱来鉴定抑制药物的新途径。
9. Comparing Manufacturer Submitted and Pan-Canadian Oncology Drug Review Reanalysed Incremental Cost-Effectiveness Ratios for Novel Oncology Drugs [O] . Ronak Saluja, Tina Jiao, Liza Koshy, 2021

机译：比较制造商提交和泛加拿大肿瘤药物审查了新型肿瘤药物的成绩增量成本效益比
10. A study of the value of requesting information from drug manufacturers for systematic reviews; 9 years of experience from the drug effectiveness review project [O] . Marian S. McDonagh, Sujata Thakurta, Kim Peterson 2018

机译：研究药品厂商提供资料的价值，以进行系统评价;毒品效果审查项目的9年经验
11. Drug Manufacturers' Noncompliance with Average Manufacturer Price Reporting Requirements [R] . 2010

机译：药品制造商不符合平均制造商价格报告要求

The Drug Manufacturer as a Drug Information Resource

摘要

著录项

相似文献

相关主题

期刊订阅